MINNEAPOLIS, Sept. 10, 2014 /PRNewswire/ -- The ENDOCUFF™
Endoscopic Overtube now provided by MEDIVATORS, a leading medical
device company with over thirty years of experience in endoscopy
technology, substantially improves adenoma and polyp detection
during colonoscopies according to two separate industry studies.
The ENDOCUFF device is a small disposable plastic over-tube with
soft flexible projections. Placed over the tip of the endoscope,
the device helps increase control and flatten colonic folds to
improve mucosa examination.
With use of the ENDOCUFF device, the number of adenomas detected
per patient increased by 86% compared to standard colonoscopy
without an endoscopic overtube, stated a 2014 German study
published in the Journal of Clinical Gastroenterology. The
number of polyps detected per patient was 63% higher with notable
superior detection in the sigmoid and cecum regions. Study results
were reported at the 2014 Digestive Diseases Week in Chicago, one of the largest annual medical
conferences for specialists in gastroenterology.
"The ENDOCUFF device has proven to significantly enhance the
physician's ability to visualize and examine the mucosa," said
Jorgen Hansen, President of
MEDIVATORS. "This is crucial to achieving our goal of
improving screening and saving lives," he stated.
According to the American Cancer Society, colorectal cancer is
the second leading cause of cancer-related deaths in the United States and is expected to cause
about 50,310 deaths during 2014. Screening reduces mortality
both by decreasing incidence and by detecting cancers at earlier,
more treatable stages. It has been estimated that colonoscopy
screening has the potential to prevent about 65 percent of
colorectal cancer cases.
The ENDOCUFF device study was a randomized prospective
two-center trial with a total of 498 patients. Similar results were
reported in a 2014 U.S. multi-center study published in
Gastrointestinal Endoscopy that retroactively analyzed 318
patients at a tertiary care medical center. An additional study
conducted by the New York University
School of Medicine to determine the operator learning curve for the
ENDOCUFF device found that adenoma detection rate significantly
increased with operator experience after only four
procedures.
Hansen added that physicians are reporting the device also
assists operators in complex polyp removal. "The ENDOCUFF device
reduces slippage and acts as a 'handbrake' during EMR and
polypectomy. This helps the physician maintain a steady view during
complicated procedures while instruments are fed through the biopsy
channel," he explained.
The ENDOCUFF device is radio opaque, disposable, and does not
include latex. It is available in multiple sizes to fit most
OLYMPUS, PENTAX and FUJINON colonoscopes. The ENDOCUFF™ Endoscopic
Overtube is a registered trademark of Arc Medical Design.
About MEDIVATORS
MEDIVATORS, a wholly owned subsidiary of Cantel Medical Corp.
(NYSE: CMN), is a leading provider of infection control products
and services that ensure the safe and proper disinfection of
flexible endoscopes and other devices. Beyond the full line of
Medivators ® medical device reprocessing systems, disinfectants,
detergents and other supplies for endoscopy, Medivators also
provides sterilants, dialysate concentrates and other supplies for
renal dialysis, hollow fiber membrane filtration and separation
technologies for medical and non medical applications and liquid
chemical germicides and decontamination products and services used
in other applications for infection prevention and control.
For further information visit the Medivators website at
www.medivators.com.
About Cantel Medical Corp.
Cantel Medical (NYSE: CMN) is a leading global company dedicated
to delivering innovative infection prevention and control products
and services for patients, caregivers, and other healthcare
providers which improve outcomes, enhance safety and help save
lives. Our products include specialized medical device
reprocessing systems for endoscopy and renal dialysis, advanced
water purification equipment, sterilants, disinfectants and
cleaners, sterility assurance monitoring products for hospitals and
dental clinics, disposable infection control products primarily for
dental and GI endoscopy markets, dialysate concentrates, hollow
fiber membrane filtration and separation products, and specialty
packaging for infectious and biological specimens. Additionally, we
provide technical service for our products.
For further information, visit the Cantel website at
www.cantelmedical.com.
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. These statements involve a number of risks and uncertainties,
including, without limitation, the risks detailed in Cantel's
filings and reports with the Securities and Exchange Commission.
Such forward-looking statements are only predictions, and actual
events or results may differ materially from those projected or
anticipated.
SOURCE Cantel Medical Corp.